July 28, 2014 2:40 PM ET

Pharmaceuticals

Company Overview of Presidio Pharmaceuticals, Inc.

Company Overview

Presidio Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the discovery and development of small-molecule antiviral therapeutics for hepatitis C virus (HCV). Its product pipeline includes PPI-668, a pan-genotypic HCV NS5A inhibitor for the treatment of patients with chronic HCV; and PPI-383, a non-nucleoside polymerase inhibitor to treat HCV. Presidio Pharmaceuticals, Inc. was incorporated in 2006 and is based in San Francisco, California.

1700 Owens Street

Suite 585

San Francisco, CA 94158

United States

Founded in 2006

Phone:

415-655-7560

Fax:

415-986-2864

Key Executives for Presidio Pharmaceuticals, Inc.

Acting President
Co-Founder and Director
Chief Medical Officer
Age: 66
Vice President of Chemistry
Vice President of Regulatory Affairs
Compensation as of Fiscal Year 2014.

Presidio Pharmaceuticals, Inc. Key Developments

Presidio Pharmaceuticals, Inc. Announces Non-Exclusive Collaboration with Boehringer Ingelheim for Phase IIa Clinical Trial of an Interferon-Free, All-Oral, Direct-Acting Antiviral Combination Treatment for Patients with Chronic Hepatitis C Virus Infection

Presidio Pharmaceuticals, Inc. announced a non-exclusive collaboration with Boehringer Ingelheim for a Phase IIa clinical trial of an interferon-free, all-oral, direct-acting antiviral (DAA) combination treatment for patients with chronic hepatitis C virus (HCV) infection. The collaborative trial will evaluate Presidio's pan-genotypic HCV NS5A inhibitor (PPI-668) in combination with Boehringer Ingelheim's HCV protease inhibitor faldaprevir (BI201335) and its non-nucleoside HCV polymerase inhibitor (BI207127), with or without ribavirin. Both companies have agreed to initiate the Phase II, 12-week treatment study in the second quarter of 2013. The trial will measure on-treatment antiviral responses and sustained virologic response rates (SVR) to the triple DAA combination regimen, with or without ribavirin. Presidio Pharmaceuticals will have primary operational responsibility for the trial, in close collaboration with Boehringer Ingelheim. Sustained virologic response results at 4- and 12-weeks post-treatment are expected to be available in the fourth quarter of 2013. Both companies continue to retain all rights to their respective compounds during this collaboration.

BioCryst Pharmaceuticals, Inc., Presidio Pharmaceuticals, Inc. - M&A Call

To discuss merger termination update and BioCryst's future strategy and initiatives

BioCryst Pharmaceuticals, Inc., Presidio Pharmaceuticals, Inc. - M&A Call

To consider the acquisition of Presidio Pharmaceuticals, Inc. by BioCryst Pharmaceuticals, Inc. through the merger of a newly formed subsidiary of BioCryst with and into Presidio, with Presidio continuing as the surviving corporation; and to discuss certain financial and other information relating to the Merger and the Merger Agreement

Similar Private Companies By Industry

Company Name Region
The Tapemark Company United States
Ceragenix Corporation United States
Charles River Discovery and Imaging Services, Inc. United States
Hanford Pharmaceuticals, LLC United States
ISW Group, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Presidio Pharmaceuticals, Inc., please visit www.presidiopharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.